Eli Lilly Alzheimer’s Donanemab Slowed Disease Progression In Trial

There is potentially big news in America’s war on Alzheimer’s.

Eli Lilly reports that its treatment donanemab significantly slowed progression of the mind-robbing disease.

The company reported on a positive clinical test.

Patients showed a 35% slower decline in memory, thinking and their ability to perform daily activities compared with those who did not receive the treatment, Eli Lilly said.

Click to read full article Go back home

Sign Up for Our Newsletter

Join our list!

Sign up here to get our daily newsletter with the top trending headlines.